BRIEF — Sunovion's NDA accepted for motor fluctuations in Parkinson's

Sunovion Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD).

While OFF episodes are experienced by 40 to 60% of people living with PD, there are limited on-demand treatment options available.

East Coast, USA-based Sunovion, which is a wholly-owned subsidiary of Japan’s Sumitomo Dainippon Pharma, has been told that the FDA will make a decision by January 29.